(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 September 2025 (25.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/199179 A2

(51) International Patent Classification:
C07K 7/16 (2006.01) *A61K 38/095* (2019.01)

(21) International Application Number:
PCT/US2025/020483

(22) International Filing Date:
18 March 2025 (18.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/566,711 18 March 2024 (18.03.2024) US

(71) Applicant: **TONIX PHARMACEUTICALS HOLDING CORP.** [US/US]; 26 Main Street, Suite 101, Chatham, New Jersey 07928 (US).

(72) Inventors; and
(71) Applicants: **RIDEOUT, Darryl C.** [US/US]; 2060 Rue Sherbrooke Ouest #102, Montréal, Québec H3H 1G5 (CA). **LEDERMAN, Seth** [US/US]; 800 W. 38th St., Apartment 2209, Austin, Texas 78705 (US).

(74) Agent: **HALEY, James F., Jr.** et al.; HALEY GUILIANO LLP, 75 Broad Street, Suite 510, New York, New York 10004 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

(54) **Title:** OXYTOCIN PEPTIDE ANALOGS

FIGURE 1



(57) **Abstract:** The present disclosure relates to oxytocin peptide analogs, or an enantiomer, racemate, tautomer, hydrate, solvate thereof, or pharmaceutically acceptable salts of any of them, and pharmaceutical compositions and formulation of them and methods for the treatment of various medical conditions associated with inadequate OTR activity in subjects in need thereof. These methods comprise administration of an oxytocin peptide analog of this disclosure, or an enantiomer, racemate, tautomer, solvate, hydrate thereof, or pharmaceutically acceptable salts of any of them, or pharmaceutically acceptable compositions or formulation containing them, to a subject in need thereof.

WO 2025/199179 A2